Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

Overview of attention for article published in Advances in Therapy, October 2013

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news: 2 news outlets
policy: 4 policy sources

twitter: 1 X user
patent: 4 patents

Readers on

mendeley: 336 Mendeley

Summary News Policy documents X Patents

So far, Altmetric has seen 2 news stories from 2 outlets.

Do Interim Results Need A Warning Label?

MedPage Today, 11 Sep 2017

MedpageToday by September 11, 2017 CHICAGO -- It was a 2012 paper in the New England Journal of Medicine (NEJM) that made…

Use of Dexamethasone Mouthwash in Managing mTOR Inhibitor–Associated Stomatitis in Patients With Breast Cancer

The ASCO Post, 10 Aug 2016

I believe this mouthwash to be a new standard of care for postmenopausal women receiving everolimus/exemestane for treatment of…